Dinamarca - dinamarquês - SEGES Landbrug & Fødevarer

basf a/s - metconazol, epoxiconazol - emulsionskoncentrat - 27,5 g/l metconazol ; 37,5 g/l epoxiconazol

Dinamarca - dinamarquês - SEGES Landbrug & Fødevarer

inter-trade a/s - chlormequat-chlorid, chlormequat - flydende middel - 720 g/l chlormequat-chlorid ; (~ 559 g/l chlormequat

Dinamarca - dinamarquês - SEGES Landbrug & Fødevarer

inter-trade a/s - imazalil - flydende middel - 50 g/l imazalil

Dinamarca - dinamarquês - SEGES Landbrug & Fødevarer

syngenta nordics a/s - prosulfocarb, clodinafop-propargyl, clodinafop - emulsionskoncentrat - 800 g/l prosulfocarb ; 10 g/l clodinafop-propargyl ; (~ 8,91 g/l clodinafop)

Dinamarca - dinamarquês - SEGES Landbrug & Fødevarer

adama northern europe b.v. - clomazon - kapselsuspension - 360 g/l clomazon

Dinamarca - dinamarquês - SEGES Landbrug & Fødevarer

neudorff gmbh kg - jern (iii) fosfat - sneglekorn - 24,2 g/kg jern(iii)fosfat

Dinamarca - dinamarquês - SEGES Landbrug & Fødevarer

syngenta nordics a/s - tralkoxydim - suspensionskoncentrat - 400 g/l tralkoxydim

União Europeia - dinamarquês - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - forløbercellelimfoblastisk leukæmi-lymfom - antineoplastiske midler - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

União Europeia - dinamarquês - EMA (European Medicines Agency)

takeda manufacturing austria ag - humant protein c - purpura fulminans; protein c deficiency - antitrombotiske midler - ceprotin is indicated for prophylaxis and treatment of  purpura fulminans  coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein c deficiency.

União Europeia - dinamarquês - EMA (European Medicines Agency)

mcm vaccine b.v. - difteri toxoid, tetanus toxoid, bordetella pertussis antigener: kighoste toxoid, trådformede hæmagglutinin, pertactin, fimbriae typer 2 og 3, hepatitis b surface antigen, der er produceret i gær celler, poliovirus (inaktiveret): type 1 (mahoney), type 2 (mef-1), type 3 (saukett), produceret i vero celler/ haemophilus influenzae type b polysakkarid (polyribosylribitol fosfat), der er konjugeret til meningokok-protein. - meningitis, haemophilus; poliomyelitis; tetanus; diphtheria; whooping cough; hepatitis b - vacciner - vaxelis (dtap-hb-ipv-hib) er indiceret til primære og booster vaccination hos spædbørn og småbørn i alderen fra 6 uger, mod difteri, stivkrampe, kighoste, hepatitis b, polio og invasive sygdomme forårsaget af haemophilus influenzae type b (hib). brug af vaxelis bør være i overensstemmelse med officielle anbefalinger.